FIGURE 6.

Anti-CD200 therapy failed to show synergy with checkpoint inhibitors. Yumm1.7 cells were injected into each mouse s.c. at a dose of 5 × 10⁵/mouse. When tumors were palpable, mice (n = 5/group) were treated with 250 μg/mouse of anti-CD200 (OX-90), anti-PD-1 (RPM1-14) or αCTLA-4 (9H10) or vehicle i.p. every 3 days. Tumor growth was monitored by measuring tumor length and width every 2 days. (A–C) Anti-CD200 therapy failed to show synergy with anti-PD-1 therapy. Growth kinetics (A), AUC (B) and tumor weight (C) are shown. Ns: not significant by one way ANOVA. (D–F) Anti-CD200 therapy failed to show synergy with anti-CTLA4 therapy. Growth kinetics (D, ^∗P = 0.02; ^∗∗P = 0.005), AUC (E, ^∗P = 0.011, control vs. aCTLA4; ^∗P = 0.026, control vs. aCD200/CTLA4) and tumor weight (F, ^∗P = 0.0115, control vs. aCTLA4; ^∗P = 0.023, control vs. aCD200/CTLA4; ^∗P = 0.015, aCD200 vs. aCTLA4) are shown. Data shown represents two to three experiments with similar results. One way ANOVA was used for the comparison.